Review of epidermal growth factor receptor biology

International Journal of Radiation Oncology Biology Physics

Volumn 59, Issue 2 SUPPL., 2004, Pages S21-S26

  Herbst, Roy S ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

ABX EGF; CI 1033; Epidermal growth factor receptor (EGFR); IMC C225; OSI 774; ZD1839

Indexed keywords

AMINO ACIDS; BIOLOGICAL MEMBRANES; CHEMOTHERAPY; ENZYMES; MONOCLONAL ANTIBODIES; RADIOTHERAPY;

ENZYME RECEPTORS; TRANSMEMBRANES;

ONCOLOGY;

ANTINEOPLASTIC AGENT; CANERTINIB; CETUXIMAB; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; ICR 62; LIGAND; MATUZUMAB; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; AUTOPHOSPHORYLATION; BIOLOGY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESPONSE; DRY SKIN; ENZYME ACTIVATION; FOLLICULITIS; HEAD CANCER; HUMAN; IONIZING RADIATION; LIGAND BINDING; MACULOPAPULAR ACNEIFORM ERUPTION; METASTASIS; MOLECULE; NECK CANCER; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RASH; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SUPERINFECTION; TUMOR CELL LINE;

EID: 2342492317     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.11.041     Document Type: Article

References (51)

1. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2:2001;127-137
2. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235:1987;177-182
3. Carpenter G., Cohen S. Epidermal growth factor. Annu Rev Biochem. 48:1979;193-216
4. Herbst R.S., Langer C.J. Epidermal growth factor receptors as a target for cancer treatment The emerging role of IMC-C225 in the treatment of lung and head and neck cancer. Semin Oncol. 29:2002;27-36
5. Ennis B.W., Lippman M.E., Dickson R.B. The EGF receptor system as a target for antitumor therapy. Cancer Invest. 9:1991;553-562
6. Kondapaka S.B., Fridman R., Reddy K.B. Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. Int J Cancer. 70:1997;722-726
7. Salomon D.S., Brandt R., Ciardiello F., et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 19:1995;183-232
8. Ethier SP. Signal transduction pathways: The molecular basis for targeted therapies. Semin Radiat Oncol 2002;12:3-10
9. Fujino S., Enokibori T., Tezuka N., et al. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur J Cancer. 32A:1996;2070-2074
10. Franklin WA, Veve R, Hirsch FR, et al. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 2002;29 (Suppl 4):3-14
11. Pavelic K., Banjac Z., Pavelic J., et al. Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res. 13:1993;1133-1137
12. Veale D., Kerr N., Gibson G.J., et al. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer. 68:1993;162-165
13. Volm M., Rittgen W., Drings P. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer. 77:1998;663-669
14. Alroy I., Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis Signal diversification through combinatorial ligand-receptor interactions. FEBS Lett. 410:1997;83-86
15. Burgering B.M., Coffer P.J. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature. 376:1995;599-602
16. Liu W., Li J., Roth R.A. Heregulin regulation of Akt/protein kinase B in breast cancer cells. Biochem Biophys Res Commun. 261:1999;897-903
17. Muthuswamy S.K., Gilman M., Brugge J.S. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol Cell Biol. 19:1999;6845-6857
18. Chan T.O., Rittenhouse S.E., Tsichlis P.N. AKT/PKB and other D3 phosphoinositide-regulated kinases Kinase activation by phosphoinositide- dependent phosphorylation. Annu Rev Biochem. 68:1999;965-1014
19. Engebraaten O., Bjerkvig R., Pedersen P.H., et al. Effects of EGF, bFGF, NGF and PDGF(bb) on cell proliferative, migratory and invasive capacities of human brain-tumor biopsies in vitro. Int J Cancer. 53:1993;209-214
20. Shibata T., Kawano T., Nagayasu H., et al. Enhancing effects of epidermal growth factor on human squamous cell carcinoma motility and matrix degradation but not growth. Tumour Biol. 17:1996;168-175
21. Petit A.M., Rak J., Hung M.C., et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo Angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol. 151:1997;1523-1530
22. Goldman C.K., Kim J., Wong W.L., et al. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells A model of glioblastoma multiforme pathophysiology. Mol Biol Cell. 4:1993;121-133
23. Bowers G., Reardon D., Hewitt T., et al. The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells. Oncogene. 20:2001;1388-1397
24. Lammering G., Hewit T.H., Hawkins W.T., et al. Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization. J Natl Cancer Inst. 93:2001;921-929
25. Schmidt-Ullrich R.K., Valerie K.C., Chan W., et al. Altered expression of epidermal growth factor receptor and estrogen receptor in MCF-7 cells after single and repeated radiation exposures. Int J Radiat Oncol Biol Phys. 29:1994;813-819
26. Iliakis G. Cell cycle regulation in irradiated and nonirradiated cells. Semin Oncol. 24:1997;602-615
27. Mendelsohn J., Dinney C.P. The Willet F. Whitmore, Jr., Lectureship: Blockade of epidermal growth factor receptors as anticancer therapy. J Urol. 165:2001;1152-1157
28. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res. 3:1997;2703-2707
29. Wu X., Fan Z., Masui H., et al. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest. 95:1995;1897-1905
30. Raben D., Helfrich B., Chan D., et al. C225 anti-EGFR antibody potentiates radiation (RT) and chemotherapy (CT) cytotoxicity in human non-small cell lung cancer (NSCLC) cells in vitro and in vivo. (Abstr. 1026) Proc Am Soc Clin Oncol. 20:2001;257a
31. Lynch D.H., Yang X.D. Therapeutic potential of ABX-EGF A fully humanized anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol. 29:2002;47-50
32. Hoffman T., Hafner D., Ballo H., et al. Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines. Anticancer Res. 17:1997;4419-4425
33. Bier H., Reiffen K.A., Haas I., et al. Dose-dependent access of murine anti-epidermal growth factor receptor monoclonal antibody to tumor cells in patients with advanced laryngeal and hypopharyngeal carcinoma. Eur Arch Otorhinolaryngol. 252:1995;433-439
34. Modjtahedi H., Hickish T., Nicolson M., et al. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br J Cancer. 73:1996;228-235
35. Wakeling A.E., Barker A.J., Daview D.H., et al. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Res Treat. 38:1996;67-73
36. Woodburn J.R., Barker A.J., Gibson K.H., et al. ZD 1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development. (Abstr.) Proc Am Assoc Cancer Res. 38:1997;633
37. Woodburn J., Kendrew J., Fennell M., et al. ZD 1839 (Iressa) a selective epidermal growth factor receptor kinase inhibitor (EGFR-TKI) Inhibition of c-fos, mRNA, an intermediate marker of EGFR activation, correlates with tumor growth inhibition. (Abstr.) Proc Am Assoc Cancer Res. 41:2000;402
38. Ciardiello F., Caputo R., Bianco R., et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor- selective tyrosine kinase inhibitor. Clin Cancer Res. 6:2000;2053-2063
39. Sirotnak F.M., Zakowski M.F., Miller V.A., et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res. 6:2000;4885-4892
40. Bianco C., Tortora G., Bianco R., et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res. 8:2002;3250-3258
41. Bailey LR, Kris M, Wolf M, et al. Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib ('Iressa', ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer: IDEAL 1 and 2 (Abstr.). Proc Am Assoc Cancer Res 2003;44
42. Kris M.G., Natale R.B., Herbst R.S., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer A randomized trial. JAMA. 290:2003;2149-2158
43. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 21:2003;2237-2246
44. Natale R.B., Shak S., Aronson N., et al. Quantitative gene expression in non-small cell lung cancer from paraffin-embedded tissue specimens Predicting response to gefitinib, an EGFR kinase inhibitor. (Abstr. 763) Proc Am Soc Clin Oncol. 22:2003;190
45. Pollack V.A., Savage D.M., Baker D.A., et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358, 774 Dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther. 291:1999;739-748
46. Moyer J.D., Barbacci E.G., Iwata K.K., et al. Induction of apoptosis and cell cycle arrest by CP-358, 774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 57:1997;4838-4848
47. Baselga J., Averbuch S.D. ZD1839 ("Iressa") as an anticancer agent. Drugs. 60:2000;33-40
48. Lawrence T.S., Nyati M.K. Small-molecule tyrosine kinase inhibitors as radiosensitizers. Semin Radiat Oncol. 12:2002;33-36
49. Busam K.J., Capodieci P., Motzer R., et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol. 144:2001;1169-1176
50. Needle M.N. Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody. Semin Oncol. 29:2002;55-60
51. Cohen E.E., Rosen F., Stadler W.M., et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 21:2003;1980-1987